Schering To Fund Picovir Studies Under Development Deal With ViroPharma
Executive Summary
Schering-Plough will decide whether to fund additional development of ViroPharma's Picovir after assessing preclinical and Phase I data for an intranasal formulation of the common cold treatment in mid-2004
You may also be interested in...
Schering-Plough Licenses ViroPharma’s Pleconaril For Common Cold
Schering-Plough will assume development responsibilities from ViroPharma for intranasal pleconaril, currently in Phase II
Schering-Plough Licenses ViroPharma’s Pleconaril For Common Cold
Schering-Plough will assume development responsibilities from ViroPharma for intranasal pleconaril, currently in Phase II
Viropharma Picovir Oral Contraceptive Study Data Expected This Summer
Viropharma expects to have data from a Phase I drug interaction study of oral contraceptives and Picovir (pleconaril) in two to four months